Skip to main content
SpringerLink
Log in

A Practical Guide to the Recognition and Management of Myasthenia Gravis

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Myasthenia gravis is an autoimmune disorder of neuromuscular transmission. It is characterised by muscular weakness and fatiguability. Extrinsic ocular muscles are frequently involved at the onset of the disease; in about 15% of cases clinical signs remain confined to these areas, while in the other patients weakness becomes generalised.

Diagnosis relies on clinical history and signs, improvement on anticholinesterase injection, electromyographic signs of impaired neuromuscular transmission and serum antiacetylcholine receptor (anti-AChR) antibody titration. Apart from the anti-AChR antibody assay, no single test is specific for myasthenia gravis; it is rather their combined results that can confirm diagnosis.

The therapeutic approach varies from patient to patient and, as far as possible, should be adapted to each individual. Symptomatic drugs such as anticholinesterases improve muscle strength but seldom restore it to normal. Immunosuppressive therapy is very effective but entails the risk of severe adverse effects. Thymectomy improves the course of the disease and can increase remission rate; short term treatments are of benefit in the management of myasthenic emergencies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol 1984; 16: 519–34

    Article  PubMed  CAS  Google Scholar 

  2. Evoli A, Tonali P, Bartoccioni E, et al. Ocular myasthenia gravis: diagnostic and therapeutic problems. Acta Neurol Scand 1988; 77: 31–5

    Article  PubMed  CAS  Google Scholar 

  3. Newsom-Davis J, Willcox N, Schluep M, et al. Immunologic heterogeneity and cellular mechanisms in myasthenia gravis. Ann NY Acad Sci 1987; 505: 12–26

    Article  PubMed  CAS  Google Scholar 

  4. Oosterhuis HJGH. Myasthenia gravis: clinical neurology and neurosurgery monographs. Edinburgh: Churchill Livingstone, 1984

    Google Scholar 

  5. Oh SJ, Cho HK. Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis. Muscle Nerve 1990; 13: 187–91

    Article  PubMed  CAS  Google Scholar 

  6. Phillips LH, Melnick PA. Diagnosis of myasthenia gravis in the 1990s. Semin Neurol 1990; 10: 62–9

    Article  PubMed  Google Scholar 

  7. Howard JF, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin 1994; 12(2): 305–30

    PubMed  Google Scholar 

  8. Sanders DB, Howard JT. AAEE minimograph no. 25: single-fiber electromyography in myasthenia gravis. Muscle Nerve 1986; 9: 809–19

    Article  PubMed  CAS  Google Scholar 

  9. Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977; 7: 36–43

    Article  PubMed  CAS  Google Scholar 

  10. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48: 1246–52

    Article  PubMed  CAS  Google Scholar 

  11. Limburg PC, The TH, Hummel-Tappel E, et al. Anti-acetylcholine receptor antibodies in myasthenia gravis: pt 1. Relation to clinical parameters in 250 patients. J Neurol Sci 1983; 58: 357–70

    Article  PubMed  CAS  Google Scholar 

  12. Engel AG. Congenital myasthenic syndromes. Neurol Clin 1994; 12(2): 401–37

    PubMed  CAS  Google Scholar 

  13. Vincent A, Li Z, Hart A, et al. Seronegative myasthenia gravis: evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann NY Acad Sci 1993; 681: 529–38

    Article  PubMed  CAS  Google Scholar 

  14. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797–810

    Article  PubMed  CAS  Google Scholar 

  15. Sanders DB, Scoppetta C. The treatment of patients with myasthenia gravis. Neurol Clin 1994; 12(2): 343–68

    PubMed  CAS  Google Scholar 

  16. Ricciardi R, Rossi B, Nicora M, et al. Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation. J Neurol Neurosurg Psychiatry 1991; 54: 1061–2

    Article  PubMed  CAS  Google Scholar 

  17. Abramsky O, Aharonov A, Teitelbaum D, et al. Myasthenia gravis and acetylcholine receptor: effect of steroids on clinical course and cellular immune response to AChR. Arch Neurol 1975; 32: 684–7

    Article  PubMed  CAS  Google Scholar 

  18. Tindall RSA. Humoral autoimmunity in myasthenia gravis: effects of steroids and thymectomy. Neurology 1980; 30: 554–7

    Article  PubMed  CAS  Google Scholar 

  19. Sommer N, Melms A, Weiler M, et al. Ocular myasthenia gravis: a critical review of clinical and pathophysiological aspects. Doc Ophtalm 1993; 84: 309–33

    Article  CAS  Google Scholar 

  20. Haward CWH, Fonseca V. New treatment approaches to myasthenia gravis. Drugs 1990; 39: 66–73

    Article  Google Scholar 

  21. Johns TR. Long-term corticosteroid treatment in myasthenia gravis. Ann NY Acad Sci 1987; 505: 568–83

    Article  PubMed  CAS  Google Scholar 

  22. Evoli A, Batocchi AP, Palmisani MT, et al. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992; 32: 37–43

    Article  PubMed  CAS  Google Scholar 

  23. Hohlfeld R, Toyka KV, Besinger UA, et al. Myasthenia gravis: reactivation of clinical disease and autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985; 17: 238–42

    Article  PubMed  CAS  Google Scholar 

  24. Matell G. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann NY Acad Sci 1987; 505: 589–94

    Article  PubMed  CAS  Google Scholar 

  25. Osterman PO. Current treatment of myasthenia gravis. Prog Brain Res 1990; 84: 151–61

    Article  PubMed  CAS  Google Scholar 

  26. Hohlfeld R, Michels M, Heininger K, et al. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988; 38: 258–61

    Article  PubMed  CAS  Google Scholar 

  27. Niakan E, Harati Y, Rolak LA. Immunosuppressive drug therapy in myasthenia gravis. Arch Neurol 1988; 43: 155–6

    Article  Google Scholar 

  28. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK 506 and cyclosporine A. Ann NY Acad Sci 1993 Nov 30; 696: 9–19

    Article  PubMed  CAS  Google Scholar 

  29. Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993 Jun 21; 681: 539–51

    Article  PubMed  CAS  Google Scholar 

  30. Perlo VP, Shahani BT, Huggins CE, et al. Effect of plasmapheresis in myasthenia gravis. Ann NY Acad Sci 1981; 377: 709–24

    Article  PubMed  CAS  Google Scholar 

  31. Tindall RSA. Plasmapheresis for neurologic disorders. Curr Neurol 1990; 10: 177–93

    Google Scholar 

  32. Heininger K, Hartung HP, Toyka KV, et al. Therapeutic plasma exchange in myasthenia gravis: selective adsorption of anti-AChR autoantibodies with tryptophane-linked polyvinyl-alcohol gels. Ann NY Acad Sci 1987; 505: 898–900

    Article  Google Scholar 

  33. Antozzi C, Berta E, Confalonieri P, et al. Protein A immunoadsorption in immunosuppression-resistant myasthenia gravis. Lancet 1994; 343: 124

    Article  PubMed  CAS  Google Scholar 

  34. Cosi V, Lombardi M, Piccolo G, et al. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991; 84: 81–4

    Article  PubMed  CAS  Google Scholar 

  35. Arsura EL, Bick A, Brunner NG, et al. High dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986; 146: 1365–8

    Article  PubMed  CAS  Google Scholar 

  36. Evoli A, Palmisani MT, Bartoccioni E, et al. High-dose intravenous immunoglobulin in myasthenia gravis. Ital J Neurol Sci 1993; 14: 233–7

    Article  PubMed  CAS  Google Scholar 

  37. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993; 50: 137–9

    Article  PubMed  CAS  Google Scholar 

  38. Ahlberg R, Yi Q, Pirskanen R, et al. Clinical improvement of myasthenia gravis by treatment with a chimeric anti-CD4 monoclonal antibody. Ann NY Acad Sci 1993; 681: 552–5

    Article  PubMed  CAS  Google Scholar 

  39. Donaldson DH, Ansher M, Rutherford RB, et al. The relationship of age to outcome in myasthenia gravis. Neurology 1990; 40: 786–90

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Neurology, Catholic University, L. go F. Vito, 1,00168, Rome, Italy

    Amelia Evoli, Anna Paola Batocchi & Pietro Tonali

Authors
  1. Amelia Evoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Paola Batocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pietro Tonali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amelia Evoli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Evoli, A., Batocchi, A.P. & Tonali, P. A Practical Guide to the Recognition and Management of Myasthenia Gravis. Drugs 52, 662–670 (1996). https://doi.org/10.2165/00003495-199652050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199652050-00004

Keywords

Search

Navigation